PMID- 28944502
OWN - NLM
STAT- MEDLINE
DCOM- 20180817
LR  - 20180817
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 45
IP  - 1
DP  - 2018 Jan
TI  - Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients.
PG  - 3-9
LID - 10.1111/1346-8138.14074 [doi]
AB  - Immune reconstitution inflammatory syndrome (IRIS) represents a clinical 
      phenomenon of immune-mediated inflammation against various antigens, including 
      pathogenic microorganisms, drugs and unknown autoantigens, during recovery from 
      immunosuppressed conditions. IRIS has become well recognized in HIV-infected 
      populations. However, IRIS has seldom been recognized in HIV-negative 
      immunocompromised patients. In the last 15 years, the immunopathogenesis of 
      drug-induced hypersensitivity syndrome (DIHS) has been largely determined. 
      Laboratory data and clinical observations support the idea that DIHS represents a 
      prototype of non-HIV IRIS. Primary diseases in which non-HIV IRIS is secondary 
      include severe cutaneous adverse drug reactions, such as DIHS, autoimmune 
      diseases, collagen diseases, pregnancy and internal malignancies. Potential 
      triggers of recovery from an immune deterioration state include a discontinuation 
      or abrupt tapering of systemic steroids and/or immunosuppressants, withdrawal or 
      reduced effects of anti-tumor necrosis factor-alpha antibodies, and the use of 
      immune-checkpoint antagonists for the advanced stages of malignancies. Wide use 
      of IRIS across large populations risks oversimplification but highlights a key 
      unifying principle. Balanced sensitivity and specificity for its diagnostic 
      criteria and classification are necessary for the establishment of clinical 
      practice guidelines for non-HIV IRIS. Additionally, the development of a useful 
      combination of biomarkers is currently an urgent issue.
CI  - (c) 2017 Japanese Dermatological Association.
FAU - Sueki, Hirohiko
AU  - Sueki H
AUID- ORCID: 0000-0001-5691-7211
AD  - Department of Dermatology, School of Medicine, Showa University, Tokyo, Japan.
FAU - Mizukawa, Yoshiko
AU  - Mizukawa Y
AD  - Department of Dermatology, School of Medicine, Kyorin University, Tokyo, Japan.
FAU - Aoyama, Yumi
AU  - Aoyama Y
AD  - Department of Dermatology, School of Medicine, Kawasaki Medical University, 
      Okayama, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170925
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects
MH  - Disease Management
MH  - Drug Hypersensitivity Syndrome/diagnosis/*etiology
MH  - Female
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/*complications/diagnosis
MH  - Pregnancy
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
OTO - NOTNLM
OT  - anti-tumor necrosis factor-alpha antibodies
OT  - drug-induced hypersensitivity syndrome
OT  - immune-checkpoint antagonists
OT  - non-HIV immune reconstitution inflammatory syndrome
OT  - systemic steroid
EDAT- 2017/09/26 06:00
MHDA- 2018/08/18 06:00
CRDT- 2017/09/26 06:00
PHST- 2017/07/05 00:00 [received]
PHST- 2017/08/29 00:00 [accepted]
PHST- 2017/09/26 06:00 [pubmed]
PHST- 2018/08/18 06:00 [medline]
PHST- 2017/09/26 06:00 [entrez]
AID - 10.1111/1346-8138.14074 [doi]
PST - ppublish
SO  - J Dermatol. 2018 Jan;45(1):3-9. doi: 10.1111/1346-8138.14074. Epub 2017 Sep 25.